• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients
【24h】

Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients

机译：巨细胞胶质母细胞瘤的生存结局：20例患者的治疗管理经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Giant cell glioblastoma (GCG) is a rare subtype of glioblastoma (GBM) that is believed to carry an improved prognosis. However, given the rarity of this tumor, best management practices for GCG have yet to be ascertained. Here, we present our experience in managing GCG tumors at the University of California, San Francisco. Patients were retrospectively identified through chart review, and data pertaining to patient demographics, treatment plans, and follow-up were extracted from existing medical records. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints, respectively. In sum, we identified 22 patients who were managed or followed for GCG. Most patients (78%) initially underwent subtotal resection as primary treatment for their tumor, and most also received post-operative adjuvant therapy (90%), with radiation being the most frequently administered modality (85%). Within this institutional cohort, median OS and PFS were 15.4 months and 5.7 months, respectively. On multivariate survival analysis, age (p = 0.84), sex (p = 0.05), and adjuvant radiation plus temozolomide (p = 0.12) were not associated with prolonged OS. However, adjuvant radiation plus temozolomide was associated with longer PFS (p = 0.01), and patients receiving this therapy demonstrated a median PFS of 32.9 months versus 13.1 months. These findings confirm the comparatively improved prognosis of GCG over GBM. Moreover, they suggest that extent of resection may not significantly delay recurrence or extend survival, and that combination radiation with temozolomide may represent the optimum adjuvant paradigm to delay tumor progression. (C) 2014 Elsevier Ltd. All rights reserved.
机译：巨细胞胶质母细胞瘤（GCG）是胶质母细胞瘤（GBM）的罕见亚型，据信其预后改善。然而，鉴于这种肿瘤的罕见性，尚未确定GCG的最佳治疗方法。在这里，我们介绍在加利福尼亚大学旧金山分校处理GCG肿瘤的经验。通过图表审查回顾性鉴定患者，并从现有病历中提取与患者人口统计学，治疗计划和随访有关的数据。总生存期（OS）和无进展生存期（PFS）分别是主要终点和次要终点。总之，我们确定了22名接受过GCG治疗或随访的患者。大多数患者（78％）最初接受了大部切除术作为其肿瘤的主要治疗方法，并且大多数患者也接受了术后辅助治疗（90％），其中放射治疗是最常用的方式（85％）。在该机构队列中，OS和PFS的中位数分别为15.4个月和5.7个月。在多因素生存分析中，年龄（p = 0.84），性别（p = 0.05）和辅助放疗加替莫唑胺（p = 0.12）与OS延长无关。然而，辅助放疗加替莫唑胺与更长的PFS相关（p = 0.01），接受这种治疗的患者的中位PFS为32.9个月，而中位为13.1个月。这些发现证实了GCG的预后相对于GBM有所改善。此外，他们认为切除的程度可能不会显着延迟复发或延长生存期，而替莫唑胺联合放疗可能代表延迟肿瘤进展的最佳佐剂范例。 （C）2014 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号